about
Polymorphism located between CPT1B and CHKB, and HLA-DRB1*1501-DQB1*0602 haplotype confer susceptibility to CNS hypersomnias (essential hypersomnia)Characterization of sleep in zebrafish and insomnia in hypocretin receptor mutants.A practical guide to the therapy of narcolepsy and hypersomnia syndromesControl of sleep and wakefulnessActivity of dorsal raphe cells across the sleep-waking cycle and during cataplexy in narcoleptic dogsNarcolepsy: neural mechanisms of sleepiness and cataplexyWhat is causing excessive daytime sleepiness? Evaluation to distinguish sleep deprivation from sleep disordersHypocretin/orexin, sleep and narcolepsyPharmacotherapy options for cataplexyHistory of narcolepsy at Stanford University.Orexin Neurons Respond Differentially to Auditory Cues Associated with Appetitive versus Aversive Outcomes.Feeding-elicited cataplexy in orexin knockout mice.Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice.Orexin neurons suppress narcolepsy via 2 distinct efferent pathways.Cataplexy and Its Mimics: Clinical Recognition and Management.Reduced expression of TAC1, PENK and SOCS2 in Hcrtr-2 mutated narcoleptic dog brain.Conditional ablation of orexin/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function.Hypocretin/orexin and narcolepsy: new basic and clinical insights.Arousal effect of orexin A depends on activation of the histaminergic system.Environmental toxins and risk of narcolepsy among people with HLA DQB1*0602.Hypocretin-1 causes G protein activation and increases ACh release in rat pons.Genetic association, seasonal infections and autoimmune basis of narcolepsyNarcolepsy: current treatment options and future approachesRole of the hypocretin (orexin) receptor 2 (Hcrt-r2) in the regulation of hypocretin level and cataplexy.Novel therapies for narcolepsy.Reward-seeking behavior in human narcolepsyPharmacological management of narcolepsy.Complex movement disorders at disease onset in childhood narcolepsy with cataplexy.Clinical and neurobiological aspects of narcolepsy.Tick-borne bacterial, rickettsial, spirochetal, and protozoal infectious diseases in the United States: a comprehensive review.Sodium oxybate for narcolepsy.EFNS guidelines on management of narcolepsy.Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsyNeuropeptides as possible targets in sleep disorders.Animal models of narcolepsy.Role of orexin in modulating arousal, feeding, and motivation.Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy.The hypocretin/orexin receptor: therapeutic prospective in sleep disorders.Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls.CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome.
P2860
Q21143792-53B041F1-2AD6-4B39-A2C4-2E40EDB7798FQ21145872-36A0EB00-7E5C-4C12-B668-B89B48BF4EADQ24623713-0BE2155D-6324-486C-B6B0-0697E5F04DE4Q24634619-EA98E458-548B-4C82-BF7C-BA30994F88C8Q24678224-725DB2A6-BC8F-4174-BAE6-EC78CA246E7CQ27004322-DA87FA3F-E09D-4C68-B0CC-18AA6BD5B767Q28139377-0B10BEF9-8E33-4DA6-8D96-5544A48FE6E2Q28187653-626C126F-623F-4CA8-A04F-F857C276BFBFQ28287690-241E8E99-4BA3-46AD-A640-B75938410922Q30362536-9C71C521-2487-4C02-8259-929CDEAA52C0Q30377394-56022A56-9A5A-40A4-801E-994D76D89A73Q30490183-93C3151D-8C78-4CC0-8C93-1D0383168E5CQ30558348-AD4C7CE0-5C8C-4A8A-9229-A71B075F8501Q30569775-8BDDC540-4D61-483D-8A44-33FCF9C0DE00Q33168590-BC5A3B51-2880-463C-8AA2-1D4ADB3E80A2Q33285540-8C07EE8E-4038-4BF4-A8E3-D9AB4F0D69D9Q33575165-63BBF4EF-FD7A-4487-AD6F-BE50F6CAD8F0Q33814590-AA3D51C5-ABF8-4454-BD5F-C7E25F3FA5D5Q33934848-05EFD7C5-457A-432A-99D3-AA202830A1C4Q34092956-8E110753-1A3B-4564-9461-D111E0BDA4BAQ34277180-CCFB1F78-CF9A-45E5-B862-B24C086ED2B9Q34333298-98258F78-5773-4434-A36F-44BF325341C8Q34843237-52237255-B1A5-490C-9260-DBDFE7BF4594Q34989372-B812698F-8FF9-4D02-A0CC-0ACA4AA1FDC9Q35011921-1B6E6040-6076-400E-912D-EBAD95FF0116Q35042283-FA262B74-90FB-47DA-8562-204FD3562BBBQ35548163-8236C2EE-087A-498F-8721-62299619AC16Q35606698-1FF65B0D-4458-4C8D-ABBA-0C6BF9C0A8B6Q35995182-0A99BE27-0E44-411B-828A-F80037436665Q36070925-4D8CDF07-29CF-4A97-86DB-A09A09A1C0FAQ36558659-59C5399C-0C3F-4754-A136-3895812B6C3CQ36598957-141E6015-BA2E-4511-BB48-4CC052643D1EQ36608029-0EF9AC69-34FE-4D4B-B456-A9760069995AQ36675494-9CB3955C-0682-4A47-B87C-487DB1EE3A5AQ36764549-6C39C8E1-D174-4452-86D5-9AD4AF12695CQ36774914-301B08F2-5862-4905-9902-CD2984D4E5BBQ36891142-2876EC10-C4AC-4E0E-BDEE-E2A6F52A73ADQ36985867-A849D2C5-DA57-47E7-B3F3-B5FFECC832A2Q37083142-C87B0E19-2F31-449E-A234-68167A6CC3C7Q37083146-CFF1010E-0482-4A98-91A0-FD9A9793F3FC
P2860
description
1997 nî lūn-bûn
@nan
1997 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
name
Pharmacological aspects of human and canine narcolepsy.
@ast
Pharmacological aspects of human and canine narcolepsy.
@en
Pharmacological aspects of human and canine narcolepsy.
@nl
type
label
Pharmacological aspects of human and canine narcolepsy.
@ast
Pharmacological aspects of human and canine narcolepsy.
@en
Pharmacological aspects of human and canine narcolepsy.
@nl
prefLabel
Pharmacological aspects of human and canine narcolepsy.
@ast
Pharmacological aspects of human and canine narcolepsy.
@en
Pharmacological aspects of human and canine narcolepsy.
@nl
P1476
Pharmacological aspects of human and canine narcolepsy.
@en
P2093
P356
10.1016/S0301-0082(96)00070-6
P577
1997-05-01T00:00:00Z